BLAINJECTIONINJECTABLE
Approved
Sep 2024
Lifecycle
Growth
Competitive Pressure
30/100
Data completeness
3/8 — Basic
OCREVUS ZUNOVO (ocrelizumab and hyaluronidase) by Roche is cd20-directed antibody interactions [moa]. Approved for endoglycosidase [epc]. First approved in 2024.
Drug data last refreshed 22h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
OCREVUS ZUNOVO is a subcutaneous injection combining ocrelizumab (a CD20-directed monoclonal antibody) with hyaluronidase to enable faster, subcutaneous administration. It targets B cells in autoimmune and oncologic conditions by blocking CD20 surface antigen interactions. The hyaluronidase component facilitates subcutaneous delivery, improving patient convenience and reducing infusion burden.
Growth
Early-stage growth product with newly approved subcutaneous formulation; commercial team expansion anticipated as market adoption builds post-launch.
Mechanism of Action
CD20-directed Antibody Interactions
Pharmacologic Class:
Endoglycosidase
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
OCREVUS ZUNOVO represents a high-visibility growth opportunity in Roche's immunology and oncology portfolios, with career paths spanning commercial strategy, field execution, and medical education. Early-stage launch phase roles will focus on market penetration, payer negotiations, and clinician adoption of the subcutaneous formulation innovation.
Brand Manager
Worked on OCREVUS ZUNOVO at Roche? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.